LoParo Devon, Dunlop Boadie W, Nemeroff Charles B, Mayberg Helen S, Craighead W Edward
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
Department of Psychiatry, University of Texas at Austin, Austin, TX, USA.
Npj Ment Health Res. 2025 Feb 5;4(1):4. doi: 10.1038/s44184-025-00119-9.
Treatments for major depressive disorder (MDD) include antidepressant medications and evidence-based psychotherapies, which are approximately equally efficacious. Individual response to treatment, however, is variable, implying individual differences that could allow for prospective differential prediction of treatment response and personalized treatment recommendation. We used machine learning to develop predictor variables that combined demographic and clinical items from a randomized clinical trial. The variables predicted a meaningful proportion of variance in end-of-treatment depression severity for cognitive behavioral therapy (39.7%), escitalopram (32.1%), and duloxetine (67.7%), leading to a high accuracy in predicting remission (71%). Further, we used these variables to simulate treatment recommendation and found that patients who received their recommended treatment had significantly improved depression severity and remission likelihood. Finally, the prediction algorithms and treatment recommendation tool were externally validated in an independent sample. These results represent a highly promising, easily implemented, potential advance for personalized medicine in MDD treatment.
重度抑郁症(MDD)的治疗方法包括抗抑郁药物和循证心理疗法,二者疗效大致相当。然而,个体对治疗的反应存在差异,这意味着存在个体差异,从而有可能对治疗反应进行前瞻性差异预测并给出个性化的治疗建议。我们利用机器学习来开发预测变量,这些变量结合了一项随机临床试验中的人口统计学和临床项目。这些变量预测了认知行为疗法(39.7%)、艾司西酞普兰(32.1%)和度洛西汀(67.7%)治疗结束时抑郁严重程度的显著比例的方差,从而在预测缓解方面具有较高的准确性(71%)。此外,我们使用这些变量来模拟治疗建议,发现接受推荐治疗的患者抑郁严重程度和缓解可能性有显著改善。最后,预测算法和治疗建议工具在一个独立样本中得到了外部验证。这些结果代表了在MDD治疗的个性化医疗方面一个非常有前景、易于实施的潜在进展。